Home >> Pharmaceuticals >> Food & Beverage >>

Bone Fracture - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 80 | Code: MRS - 18272

Bone Fracture - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bone Fracture - Pipeline Review, H1 2015’, provides an overview of the Bone Fracture’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Fracture and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Fracture
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bone Fracture and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bone Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Fracture pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bone Fracture
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Fracture Overview 9
Therapeutics Development 10
Pipeline Products for Bone Fracture - Overview 10
Pipeline Products for Bone Fracture - Comparative Analysis 11
Bone Fracture - Therapeutics under Development by Companies 12
Bone Fracture - Therapeutics under Investigation by Universities/Institutes 14
Bone Fracture - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Bone Fracture - Products under Development by Companies 17
Bone Fracture - Products under Investigation by Universities/Institutes 18
Bone Fracture - Companies Involved in Therapeutics Development 19
Arcarios BV 19
AstraZeneca PLC 20
Biogenomics Limited 21
Bone Therapeutics SA 22
Escape Therapeutics, Inc. 23
Juventas Therapeutics, Inc. 24
Kaken Pharmaceutical Co., Ltd. 25
Kolon Life Science, Inc. 26
Kuros Biosurgery AG 27
Laboratorios SALVAT S.A. 28
Novartis AG 29
OrgaNext Research BV 30
TissueGene, Inc. 31
Viking Therapeutics, Inc. 32
Bone Fracture - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
(nandrolone decanoate + cholecalciferol) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ALLOB - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AZD-2858 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
bimagrumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
denosumab biosimilar - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
dibotermin alfa - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Gene Therapy for Bone Fracture - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
JVS-200 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KCB-1B - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KLS-Bfr - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KUR-111 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
KUR-113 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
LWnt-3a - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OsteoStem - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Recombinant Protein to Activate TNF alfa for Fracture Repair - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Stem Cell Therapy for Bone Regeneration - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Stromal Cell Therapy for Fracture Repair - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
TG-B - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
VK-5211 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Bone Fracture - Recent Pipeline Updates 69
Bone Fracture - Dormant Projects 72
Bone Fracture - Discontinued Products 73
Bone Fracture - Product Development Milestones 74
Featured News & Press Releases 74
Mar 23, 2015: Bone Therapeutics treats first patients in ALLOB Phase IIA spinal fusion trial 74
Jan 19, 2015: Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB Phase I/IIA Delayed-Union Trial 74
Dec 16, 2014: Bone Therapeutics Confirms Safety in ALLOB® Phase I/IIa Trial for Delayed-Union Fractures 75
Oct 09, 2014: Bone Therapeutics extends ALLOB phase I/IIa trial to Germany 75
Jun 25, 2014: Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product 76
Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial 77
Aug 29, 2013: Researcher Awarded $5 Million to Advance Future Stem Cell Treatments for Segmental Bone Fractures 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables
Number of Products under Development for Bone Fracture, H1 2015 10
Number of Products under Development for Bone Fracture - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Bone Fracture - Pipeline by Arcarios BV, H1 2015 19
Bone Fracture - Pipeline by AstraZeneca PLC, H1 2015 20
Bone Fracture - Pipeline by Biogenomics Limited, H1 2015 21
Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2015 22
Bone Fracture - Pipeline by Escape Therapeutics, Inc., H1 2015 23
Bone Fracture - Pipeline by Juventas Therapeutics, Inc., H1 2015 24
Bone Fracture - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 25
Bone Fracture - Pipeline by Kolon Life Science, Inc., H1 2015 26
Bone Fracture - Pipeline by Kuros Biosurgery AG, H1 2015 27
Bone Fracture - Pipeline by Laboratorios SALVAT S.A., H1 2015 28
Bone Fracture - Pipeline by Novartis AG, H1 2015 29
Bone Fracture - Pipeline by OrgaNext Research BV, H1 2015 30
Bone Fracture - Pipeline by TissueGene, Inc., H1 2015 31
Bone Fracture - Pipeline by Viking Therapeutics, Inc., H1 2015 32
Assessment by Monotherapy Products, H1 2015 33
Assessment by Combination Products, H1 2015 34
Number of Products by Stage and Target, H1 2015 36
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 42
Bone Fracture Therapeutics - Recent Pipeline Updates, H1 2015 69
Bone Fracture - Dormant Projects, H1 2015 72
Bone Fracture - Discontinued Products, H1 2015 73

List of Figures
Number of Products under Development for Bone Fracture, H1 2015 10
Number of Products under Development for Bone Fracture - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Early Stage Products, H1 2015 16
Assessment by Monotherapy Products, H1 2015 33
Number of Products by Top 10 Targets, H1 2015 35
Number of Products by Stage and Top 10 Targets, H1 2015 36
Number of Products by Top 10 Mechanism of Actions, H1 2015 37
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 38
Number of Products by Top 10 Routes of Administration, H1 2015 39
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 40
Number of Products by Top 10 Molecule Types, H1 2015 41
Number of Products by Stage and Top 10 Molecule Types, H1 2015 42

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing